Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma
Roger Gilabert-Oriol, Sebastian GB Furness, Brett W Stringer, Alexander Weng, Hendrik Fuchs, Bryan W Day, Angela Kourakis, Andrew W Boyd, David L Hare, Mayank Thakur, Terrance G Johns, Peter J Wookey
CANCER IMMUNOLOGY IMMUNOTHERAPY | SPRINGER | Published : 2017
Awarded by National Health and Medical Research Council of Australia
Dr Furness was supported by the National Health and Medical Research Council of Australia (Program Grant 1055134 and Project Grant 1061044). Dr Gilabert-Oriol was supported by an Endeavour Research Fellowship (Australian Government). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors are grateful for the gift of rGelonin from Professor Rosenblum of the University of Texas MD Anderson Cancer Center, Texas, USA. Confocal microscopy was performed at the Biological Optical Microscopy Platform, The University of Melbourne (http://www.microscopy.unimelb.edu.au) and the Leibniz-Institut fur Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Berlin, Germany. Thanks go to the team at the Antibody Facility (Walter and Eliza Hall Institute, Bundoora) for production of the anti-CTR antibodies.